| Outcome | Baseline | 6-mo Follow-up |
Median Change |
Between-Group Difference (95% CI) |
PValue |
|---|---|---|---|---|---|
| Median Duodenal Polyp Burden, mm | |||||
| Sulindac-erlotinib | 29.0 | 19.5 | −8.5 | −19.0 (−32.0 to −10.9) | <.001 |
| Placebo | 23.0 | 31.0 | 8.0 | ||
| Median Duodenal Polyp Count, No. | |||||
| Sulindac-erlotinib | 13.5 | 10.0 | −2.8 | −8.0 (−12.2 to −4.7) | <.001 |
| Placebo | 10.5 | 17.0 | 4.3 | ||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.